Introduction
The c-kit proto-oncogene encodes a receptor tyrosine kinase. Binding of c-kit ligand, stem cell factor (SCF) to c-kit receptor (c-kitR) is known to activate c-kitR tyrosine kinase, thereby leading to autophosphorylation of c-kitR on tyrosine and to association of c-kitR with substrates such as phosphatidylinositol 3-kinase (P13K). In a human mast cell leukemia cell line HMC-1, c-kitR was found to be constitutively phosphorylated on tyrosine, activated, and associated with PI3K without the addition of SCF. The expression of SCF mRNA transcript in HMC-1 cells was not detectable by means of PCR after reverse transcription (RT-PCR) analysis, suggesting that the constitutive activation of c-kitR was ligand independent. Sequencing of whole coding region of c-kit cDNA revealed that c-kit genes of HMC-1 cells were composed ofa normal, wild-type allele and a mutant allele with two point mutations resulting in intracellular amino acid substitutions of Gly-560 for Val and Val-816 for Asp. Amino acid sequences in the regions of the two mutations are completely conserved in all of mouse, rat, and human c-kit. In order to determine the causal role of these mutations in the constitutive activation, murine c-kit mutants encoding Gly-559 and/or Val-814, corresponding to human Gly-560 and/or Val-816, were constructed by site-directed mutagenesis and expressed in a human embryonic kidney cell line, 293T cells. In the transfected cells, both c-kitR (Gly-559, Val-814) and ckitR (Val-814) were abundantly phosphorylated on tyrosine and activated in immune complex kinase reaction in the absence of SCF, whereas tyrosine phosphorylation and activation of c-kitR (Gly-559) or wild-type c-kitR was modest or little, respectively. These results suggest that conversion of to Val in human c-kitR may be an activating mutation and responsible for the constitutive activation of c-kitR in HMC-1 cells. (J. Clin. Invest. 1993. 92:1736-1744.) Key words: protooncogene c-kit-point mutation * leukemia -tyrosine kinaseactivation
The proto-oncogene c-kit was identified as the cellular homologue of the oncogene v-kit present in the genome of HardyZuckerman 4-feline sarcoma virus that induces multicentric fibrosarcomas in the domestic cat ( 1) . The proto-oncogene c-kit encodes a transmembrane tyrosine kinase receptor that is a member of receptors for PDGF and CSF-1 (2, 3) . The characteristic features of the receptor tyrosine kinase subfamily are an extracellular domain made up of five immunoglobulin-like repeats, and an intracellular tyrosine kinase, which is split into two domains by a hydrophilic insert sequence (1) (2) (3) (4) . The ligand for c-kit product has recently been cloned and variously designated as stem cell factor (SCF),' mast cell growth factor, kit ligand, or steel factor (5) (6) (7) (8) (9) (10) (11) (12) .
The c-kit gene is allelic with the dominant white spotting (W) locus on mouse chromosome 5 (13, 14) , whereas the gene encoding SCF resides at steel (SI) locus on mouse chromosome 10 (7, 9, 12) . Mutations at either the W/c-kit locus or the SI /SCF locus affect various aspects of hematopoiesis and the proliferation and/or migration of primordial germ cells and melanoblasts during embryogenesis (4, (15) (16) (17) . In hematopoiesis, both WI c-kit and SI /SCF mutations affect the hematopoietic stem cell compartment and give rise to hypoplastic anemia and a deletion of mast cells (4, (15) (16) (17) . Recent experiments have shown that c-kit product is expressed on mast cells (4, 16, 18) and on a small, progenitor-cell fraction ( -4%) ofadult bone marrow cells (19) (20) (21) , and that SCF acts synergistically with other hematopoietic growth factors to stimulate the growth of a variety of progenitor cells (5, 6, (22) (23) (24) .
In addition to normal hematopoietic cells, we and others have investigated the expression and function of c-kit product in human leukemia cells (25) (26) (27) (28) (29) (30) (31) (32) . In human leukemia cell lines, the expression of c-kit product was detected in erythroleukemia cell lines (HEL, LAMA, and TF-1), megakaryocytic leukemia cell lines (MO7E and MEG-0 1), and mast-cell leukemia cell line (HMC-l ) (25, 27, 31, 32) . Also, c-kit product was found to be expressed in most cases ofhuman acute myeloblastic leukemia (AML) and in some cases ofchronic myelogenous leukemia (CML) in blastic crisis (26, (28) (29) (30) (31) . Further, SCF induced rapid tyrosine phosphorylation and activation of c-kit product, leading to proliferation ofM07E cells and blast cells in a substantial fraction of AML cases (27, 28) . These results suggest that c-kit activation may be involved in some aspect of excessive proliferation and aberrant differentiation of human leukemia cells. However, structural abnormalities of c-kit gene contributing to constitutive, ligand-independent activation of the c-kitR kinase have not been reported.
In this study, we have investigated the state of tyrosine phosphorylation and activation of c-kit product in human leukemia cells, and found that, regardless ofstimulation with SCF, c-kit product is constitutively phosphorylated on tyrosine residues in HMC-1. Neither SCF mRNA transcript nor biological activity of SCF were detectable from HMC-1 cells, suggesting that the activation of c-kit was not due to autocrine mechanism. The sequence of the c-kit gene revealed unique, as-yetunidentified, two-point mutations in the cytoplasmic domain, resulting in amino acid substitutions of Gly for Val in codon 560 and Val for Asp in codon 816. Further, introduction ofthe mutated c-kit genes into cells of a human embryonic kidney cell line, 293T, resulted in the generation of the c-kit-encoded protein that was constitutively phosphorylated on tyrosine and activated without the addition of SCF. Thus, our data provide the first evidence that point mutation(s) in c-kit gene is capable of inducing constitutive activation of c-kit product, and raise the possibility that the activating mutation(s) described here may be involved in oncogenesis ofsome cell types, including mast cells and hematopoietic stem cells.
Methods
Reagents. Highly purified recombinant human (rh) GM-CSF (rhGM-CSF) was a gift from Drs. S. Clark and G. Wong (Genetic Institute, Cambridge, MA). rhSCF was generously provided by Dr. K. M. Zsebo (Amgen Inc., Thousand Oaks, CA). The anti-phosphotyrosine antibody, a murine mAb generated against phosphotyramine, was generously supplied by Dr. B. Druker (Dana-Farber Cancer Institute, Boston, MA). The specificity of the anti-phosphotyrosine mAb was described previously (33, 34) . Rabbit anti-human c-kit serum was kindly provided by Dr. A. Ullrich (Max-Planck Institute ftir Biochemie, Martinsried, Germany). This antiserum was generated against a synthetic peptide corresponding to COOH-terminal 16 amino acid residues of c-kitR (2) . A murine mAb (YB5.B8) that reacts with the extracellular domain of human c-kit protein was originally raised against human AML blast cells (21, 35) . The rabbit antiserum against the whole murine c-kit protein (36) was generously donated by Dr. P. Besmer (Cor- nell University Graduate School of Medical Science, New York). A rat mAb (ACK-2) against the extracellular domain of murine c-kit product ( 19) and the full length of murine c-kit cDNA clone were generously donated by Dr. S-I. Nishikawa (Kumamoto University, Kumamoto, Japan). Rabbit anti-phosphatidylinositol 3-kinase (PI3K) serum was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY); the anti-PI3K serum recognizes an 85-kD subunit of P13K.
Chemically defined serum-free medium (ASF-102) was purchased from Ajinomoto (Tokyo, Japan); it contains human transferrin, insulin, and BSA.
Cell lines. HMC-1, a human mast cell leukemia cell line, established from the peripheral blood from a patient with mast cell leukemia, was grown in Iscove's modified Dulbecco's medium supplemented with 10% horse serum (Flow Lab, North Ryde, Australia) as described previously (37 Immunoblotting. The procedures of cell lysis, gel electrophoresis, and immunoblotting were performed according to the methods described previously (27, 28, 33, 34 anti-PI3K serum.
Immune complex kinase assay. The cell lysates were prepared from rhSCF-unstimulated cells using NP-40 lysis buffer. The product of c-kit was immunoprecipitated with the YB5.B8 mAb and protein A-Sepharose beads, and the immune complexes were washed once with PBS, twice with 0.5 M LiCl and 50 mM Tris-HCl, pH 7.4, and once with kinase buffer (10mM MnCl2, 20 mM Tris-HCl, pH 7.4) at 4°C. Then, the immune complexes were incubated in kinase buffer containing 10 ;tCi/ml [y-32P]ATP (DuPont/NEN Research Products, Boston, MA) for 20 min at 25°C, washed, and separated by SDS-PAGE. The gel was dried, and radioactive proteins were detected by autoradiography.
Oligonucleotide primers. PCR was performed by using two complementary oligonucleotide primers for amplifying human SCF cDNA: 5'-ATGAAGAAGACACAACTTG-3'(184 to 203, sense)and 5'-AAG-GCATCAATGGATCTATT-3'(615 to 634, antisense). For the amplification of human c-kit cDNA, the following seven oligonucleotide primers were used: primer 1, 5'-GATCCCATCGCAGCTACCGCG-3' Sequencing ofc-kit cDNA. Sequencing of the whole coding region of c-kit cDNA was performed in HMC-I cells by using four sets of primers: primers 1-4, 2-6, 3-6, and 5-7 as described above. The PCR products amplified by these primers were gel purified, sequentially treated with T4 polynucleotide kinase and the Klenow fragment of DNA polymerase I, and subcloned into the EcoRV site of Bluescript KS(-) (Stratagene Corp., La Jolla, CA). DNA sequences of four subclones obtained from each PCR product were determined and compared with normal sequence of human c-kit cDNA (2) . The DNA sequencing reaction was performed by the method ofSanger et al. (42) using [32P]a-deoxycytidine triphosphate (DuPont/NEN Research Products). In order to further confirm the mutations of c-kit mRNA, the sequencing in the regions ofc-kit mutations was performed directly using DNA fragments amplified by independent RT-PCR.
Site-directed mutagenesis and transfection. To directly examine the causal role of the c-kit mutations in activation of c-kit tyrosine kinase activity, site-directed mutagenesis was performed using murine c-kit cDNA because ofthe following reasons. First, amino acid sequences in the regions of the two c-kit mutations are completely conserved between mouse and human. Second, human SCF is known to have little effect on cells expressing murine c-kit receptor (c-kitR) (6, 7) , whereas murine SCF can exert its actions through interaction with both murine and human c-kitRs (6, 7, 27, 43) . We therefore used a combination of murine c-kit cDNA and a human 293T cell line as a transfectant.
The gene encoding murine wild-type c-kitR was cloned into Bluescript I KS(-) and the orientation of the insert was determined by sequencing. Single-stranded uracil-containing DNA was prepared from Escherichia coli strain CJ236 (dut-ung-) as described by Kunkel (44 The labeled c-kit product was then immunoprecipitated with a rat anti-mouse c-kit mAb (ACK-2) and analyzed by SDS-PAGE and autoradiography. For the analysis of protein tyrosine phosphorylation in the transfectants, cell lysates were subjected to SDS-PAGE and immunoblotting with an anti-phosphotyrosine mAb. To examine the activation and tyrosine phosphorylation ofc-kit product, c-kit product of each transfectant was immunoprecipitated with rabbit antiserum against murine c-kit protein from the lysates, and then subjected to in vitro immune complex kinase assay and immunoblotting with an antiphosphotyrosine mAb as described above.
Results
Constitutive tyrosinephosphorylation ofc-kit product in HMC-I cells. The expression ofc-kit product was first examined with an anti-c-kit mAb, YB5.B8, which recognizes the extracellular domain of human c-kit product (35) . Flow cytometry analysis showed that c-kit product was expressed on HMC-1, M07E, and HEL cells at an almost equal level (Fig. 1 A) . Despite the high level of c-kit expression on HMC-1 cells, proliferation of HMC-I cells was not augmented by the treatment with rhSCF (data not shown), whereas rhSCF was reported to induce proliferation of M07E and HEL cells (27, 31 ).
To examine the impaired effect of rhSCF on proliferation ofHMC-1 cells, we investigated the effect of rhSCF on tyrosine kinase activity in HMC-1, M07E, and HEL cells. The cells were removed from growth factors for 16 h and then stimulated with 100 ng/ml of rhSCF for 15 min at 37°C. Changes in tyrosine phosphorylation were detected by immunoblotting with a mAb specific for phosphotyrosine. After stimulation of M07E and HEL cells with rhSCF, increased phosphotyrosine was observed in proteins particularly at molecular mass of 145 kD (Fig. 1 B) . In HMC-1 cells, by contrast, tyrosine phosphorylation of 145-kD protein was observed even in the absence of exogenous rhSCF, and rhSCF treatment resulted in only a modest increase in tyrosine phosphorylation of the protein (Fig. 1 B) .
In order to determine if the 145 protein was c-kit product, c-kit product was immunoprecipitated and analyzed by immunoblotting with either anti-phosphotyrosine mAb or anti-c-kit serum. As shown in Fig. 1 C, tyrosine phosphorylation ofc-kit product was detected in HMC-I cells regardless ofrhSCF stimulation, while it was considerably increased by stimulation with rhSCF in M07E and HEL cells.
Activation ofc-kit product in HMC-J cells. Ligand binding to c-kit product is known to activate the c-kit receptor tyrosine kinase, thereby leading to c-kit-tyrosyl autophosphorylation and the association ofc-kit with its substrates such as phosphatidylinositol 3-kinase (PI3-kinase) (4, (46) (47) (48) . To determine whether or not the constitutive tyrosine phosphorylation of c-kit product in HMC-l cells was accompanied by activation of c-kit receptor tyrosine kinase, we examined the association of c-kit product with P13K and the autokinase activity of c-kit products in the cells.
HMC-1, M07E, and HEL cells were factor starved and exposed to medium alone or rhSCF (100 ng/ml) for 15 min at 37°C, and then lysed with lysis buffer containing 1% digitonin. Before and after stimulation with rhSCF, c-kit products were immunoprecipitated with a YB5.B8 mAb from the cell lysates and divided into two aliquots, one of which was subjected to Figure 2 . Association of c-kit product with P13K in HMC-1, M07E, and HEL cells. Cells were treated with rhSCF (100 ng/ml) for 15 min at 370C and lysed with 1% digitonin. c-kit product and c-kit-associated molecules were immunoprecipitated with YB5.B8 and protein A-Sepharose beads from the cell lysates before and after stimulation with rhSCF. The immunoprecipitates were divided into two aliquotes, separated by SDS-PAGE, and subjected to immunoblot analyses of P13K (upper panel) and c-kit product (lower panel).
readily detectable in HMC-l cells in the absence of SCF stimulation, whereas it was only faint in M07E or HEL cells (Fig. 3) . In this experiment, almost equal amounts of c-kit products were immunoprecipitated in these samples (data not shown). for Asp, respectively. These two point mutations were observed in cDNA clones generated from three independent PCR products, and also confirmed by direct sequencing ofPCR products amplified independently (Fig. 5) . Further, sequencing of cDNA fragment (nucleotides 964 through 2594) covering the regions of both mutations was performed in four subclones. This analysis showed that two subclones had both mutations, but the remaining two subclones had neither mutation. These results indicate that c-kit genes ofHMC-1 cells are composed of a normal wild-type allele and a mutant allele with two point mutations.
In addition, the deletions of 12-nucleotide sequence (nucleotides 1550 through 1561), the extracellular 4-amino acid sequence (Gly-Asn-Asn-Lys), and 3-nucleotide sequence (nucleotides 2163 through 2165) were observed in both normal and mutant alleles of HMC-1. The former deletion was previously reported to be due to alternative splicing ofmRNA (49); the latter was also considered as the result of alternative splicing of mRNA between exon 14 and 15, in light of data on the human c-kit genome (50).
Mutation(s) leads to activation of c-kit receptor tyrosine kinase. Amino acid sequences in the regions of the two c-kit mutations identified in HMC-l cells are completely conserved in all of mice, rats, and humans. In order to determine the direct role ofthe c-kit mutations in ligand-independent activation of c-kit products, the expression vectors containing normal or mutated murine c-kit genes were transfected into cells of a human embryonic kidney cell line, 293T. This combination could minimize the effect ofSCF, which might be produced by the transfected cells, on c-kit product expressed on 293T cells (see Methods).
We used site-directed mutagenesis to construct mutant murine c-kitR containing substitutions of Gly for Val at codon 559 and/or Val for Asp at codon 814, which corresponded to Gly-560 and/or Val-816 of mutant human c-kitR, respec- tively. When wild-type or mutated c-kit genes were transfected in 293T cells, the c-kit gene products were synthesized in the cells as 145-and 125-kD proteins (Fig. 6 A) , which were the mature and immature forms of c-kit products, respectively (51) . Although each transfectant expressed approximately equal amounts of c-kit products, a major c-kit product that incorporated [35S]methionine was the immature form in the cells expressing c-kitR (Gly-559, Val-814) or c-kitR (Val-814), whereas it was the mature form in the cells expressing c-kitR (Gly-559) or wild-type c-kitR (Fig. 6 A) .
Before and after transfection ofc-kit genes, changes in tyrosine phosphorylation ofproteins were detected by immunoblotting with anti-phosphotyrosine mAb (Fig. 6 B) . As compared with nontransfected 293T cells, little or no increase in tyrosine phosphorylation was observed in the cells expressing wild-type c-kitR. However, a number of proteins, including 125-and 145-kD proteins, were heavily phosphorylated on tyrosine in the cells expressing c-kitR (Val-814) or c-kitR (Gly-559, Val-814). Also, a modest degree of tyrosine phosphorylation of 125-and 145-kD proteins was noted in the cells expressing c-kitR (Gly-559).
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In order to further examine the tyrosine phosphorylation and activation of c-kit products in the transfected cells, c-kit products were immunoprecipitated and assayed by immunoblotting with an anti-phosphotyrosine mAb and also for autokinase activity. In the absence of SCF, both c-kitR (Val-814) and c-kitR (Gly-559, Val-814) were found to be abundantly phosphorylated on tyrosine, and c-kitR (Val-814) was also phosphorylated on tyrosine, albeit to a much lesser degree, whereas wild-type c-kitR was not (Fig. 7 A) . Further, in accord with the findings on the immunoblotting analysis, immune complex kinase assay showed a striking autokinase activity in both c-kitR (Val-814) and c-kitR (Gly-559, Val-814), a weak activity in c-kitR (Gly-559), and little or no activity in wildtype c-kitR in the absence of SCF (Fig. 7 B) .
Discussion
Many receptor tyrosine kinases were first identified as retroviral oncogenes such as v-erbB, v-fms, and v-kit that encode oncogenic forms of epidermal growth factor R (EGFR), CSF-1 R, and c-kitR, respectively (1, 46, 52 tide sequencing analyses revealed a variety of structural differences between the oncogenes and their proto-oncogenes: verbB and v-kit proteins lack the extracellular binding domain of the receptors that negatively regulates the receptor tyrosine kinase activity; v-fms differs from c-fms by nine scattered amino acid substitutions and by a COOH-terminal structure (3, 46, 53, 54) . These structural alterations in the oncogenes activate constitutively the tyrosine kinase function, thereby leading to cell transformation and tumorigenicity (46) . In addition, it has been reported that even point mutations in a proto-oncogene can lead to activation of the corresponding tyrosine kinase receptor, as has been shown by "activating" mutations of c-fms that induce morphologic transformation, anchorage-independent growth, and tumorgenicity in mouse NIH 3T3 cells (53, 54) . In the case of c-kit, however, all of mutations so far described in mice, rats, and humans are reported to affect either the structure of c-kit or c-kit expression, resulting in a decrease in c-kit tyrosine kinase activity (4) .
In this study, we have shown that c-kit product is constitutively phosphorylated on tyrosine and activated in HMC-1 cells even in the absence of SCF-stimulation. Further, c-kit product was found to be associated with PI3K without the exogenous SCF. The ligand-induced association of c-kit product with P13K is reported to depend on autophosphorylation of c-kit product on tyrosine residues where the association occurs (48) . Therefore, tyrosine residues that are constitutively phosphorylated in HMC-1 cells may be indistinguishable from those phosphorylated by ligand stimulation. However, neither mRNA transcript nor biological activity of SCF were detectable from HMC-1 cells. These results suggest that c-kit product in HMC-1 cells is constitutively activated in a ligand-independent manner.
Sequencing analyses have revealed that c-kit genes of HMC-l cells are composed of a normal, wild-type allele and a mutant allele with two point mutations resulting in amino acid substitutions of Gly-560 for Val and Val-816 for Asp in the intracellular domain. In order to analyze the effect of these previously unidentified substitutions on c-kit kinase function, mutated murine c-kit genes encoding murine c-kitR (Gly-559 and/or Val-814), which were constructed by site-directed mutagenesis to correspond to human c-kitR (Gly-560 and/or Val-816), were transfected in a human embryonic kidney cell line, 293T cells. In the transfected cells, wild-type c-kitR was neither phosphorylated on tyrosine in vivo nor activated in immune complex kinase reaction in the absence of SCF. By contrast, both c-kitR (Gly-559, Val-814) and c-kitR (Val-814) were strikingly phosphorylated on tyrosine and activated in the absence of SCF. Further, c-kitR (Gly-559) was also phosphorylated on tyrosine and activated, albeit to a much lesser degree. Given the fact that human SCF is hardly active on murine c-kitR (6, 7) even ifit might be produced from 293T cells, these results indicate that conversion ofaspartic acid-814 to valine in murine c-kitR is an activating mutation and considerably more efficient than that of valine-559 to glycine in inducing c-kit kinase activity. It is therefore suggested that a mutation of human c-kit gene at codon 816 (Asp -* Val) plays a major role in the constitutive activation of c-kit product in HMC-1 cells, while a mutation at codon 560 (Val --Gly) has a minor role.
The activating mutation of c-ffms gene is reported to affect intracellular transport of human CSF-1R (54 (49) . This shorter form of c-kit is found in the half of normal murine or rat c-kit cDNA clones (40, 49 considerably more active than the shorter form of c-kit, and that the shorter form is unlikely to contribute to the constitutive activation of c-kit product in HMC-1 cells. Although the mutations described here are found to lead to the constitutive activation of c-kit tyrosine kinase activity, the role of the c-kit activating mutations in leukemogenesis remains to be elucidated. In a previous study, we showed that c-kit product was phosphorylated on tyrosine in freshly prepared leukemic cells of some AML cases even in the absence of SCF stimulation (28) . However, occurrences oftyrosine phosphorylation of c-kit product observed in the AML cases were not so striking as that in HMC-1 cells (28) . Therefore, an activating mutation at residue 816 (Asp --Val) may not occur frequently in de novo AML, while it is still possible that certain mutations of c-kitR other than c-kitR (Val-8 16) may contribute to the modest degree of c-kit activation in AML cells. It is interesting to note that HMC-l is a human mast-cell leukemia cell line (37) , and that a mouse mastocytoma cell line, P-8 15,
has also been reported to exhibit constitutive activation of ckitR in the absence of detectable autocrine production of SCF (48) , although the sequence of the c-kit alleles expressed by P-8 15 cells is not characterized at this time. Further, a c-kitR/ SCF system is known to play a crucial role in the growth and differentiation of mast cells (4, 16) . It has been recently reported that apparently selective growth of human mast cells is observed in long-term culture of human cord-blood or bonemarrow cells exceptionally with either murine or human SCF but not with other hematopoietic growth factors (43, 55, 56 mice results in the development of lethal systemic mast cell leukemia, and suggested that v-erbB may use parts of a signal transduction pathway normally coupled to c-kitR (57) . These findings raise the possibility that activating mutations of c-kit described here may be involved in neoplastic transformation of mast cells, although it is as yet unclear whether these mutations by themselves can lead to factor-independent growth and tumorgenicity. It would be of considerable interest to examine whether the transfection of nontumorigenic or factor-dependent cell lines with the mutant forms ofc-kit genes results in the production ofa tumorigenic or factor-independent phenotype. In addition to hematological malignancies, expression of c-kit proto-oncogene has been found in various tumors such as lung cancer and germ cell tumors (58, 59). Further, the amino acid sequence in a region ofthe kinase domain containing Asp-816 of human c-kit product is widely conserved in many other RTKs such as receptors for PDGF, CSF-1, and insulin (60). Therefore, it is possible that the unique activating mutation in codon 816 of human c-kitR, or a similar mutation in other RTKs, may participate in the development of a variety of malignancies. Further studies on c-kit mutants will be necessary to understand the mechanisms by which growth factor receptors influence oncogenesis and normal growth control.
